Trial Profile
A Multicentre, Open-Label, Phase 2 Safety Extension Study to Evaluate the Safety and Tolerability of R-107 in subjects with Refractory Major Depressive Disorder.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Ketamine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Acronyms BEDROC-1
- Sponsors Douglas Pharmaceuticals
- 06 Dec 2021 Planned number of patients changed from 120 to 150.
- 06 Dec 2021 Planned End Date changed from 2 Feb 2022 to 15 Feb 2022.
- 06 Dec 2021 Status changed from recruiting to active, no longer recruiting.